A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke
Public ClinicalTrials.gov record NCT00073476. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.
Study identification
- NCT ID
- NCT00073476
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Pfizer
- Industry
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Interventions
- traxiprodil (CP-101,606) Drug
Drug
Eligibility (public fields only)
- Age range
- 40 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2003
- Primary completion
- Not listed
- Completion
- Jan 31, 2005
- Last update posted
- Jun 21, 2006
2003 – 2005
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | La Mesa | California | 91942 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30342 | — |
| Pfizer Investigational Site | Fort Wayne | Indiana | 46804 | — |
| Pfizer Investigational Site | Fort Wayne | Indiana | 46805 | — |
| Pfizer Investigational Site | Louisville | Kentucky | 40202 | — |
| Pfizer Investigational Site | Salisbury | North Carolina | 28144 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45406 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45408 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45409 | — |
| Pfizer Investigational Site | Dayton | Ohio | 45415 | — |
| Pfizer Investigational Site | Allentown | Pennsylvania | 18103 | — |
| Pfizer Investigational Site | Philadelphia | Pennsylvania | 19141 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00073476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 21, 2006 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00073476 live on ClinicalTrials.gov.